TERBINAFINE THERAPY MAY BE ASSOCIATED WITH THE DEVELOPMENT OF PSORIASIS DE-NOVO OR ITS EXACERBATION - 4 CASE-REPORTS AND A REVIEW OF DRUG-INDUCED PSORIASIS

Adverse effects may occur in 10.4% of patients receiving terbinafine t herapy, with cutaneous reactions in 2.7%. We describe the development of psoriasis in four patients who took oral terbinafine. Two patients had plaque-type psoriasis that flared 12 and 17 days, respectively, af ter starting terbinafine. Another patient developed pustular-type psor iasis de novo after 27 days of terbinafine therapy. The fourth patient was a psoriatic with stable plaque disease who experienced a pustular flare after taking terbinafine for 21 days. We are aware of only one report in the literature in which a patient developed pustular psorias is de novo after 5 days of terbinafine therapy. Tn all patients the ps oriasis cleared or lessened after discontinuation of terbinafine and i nstitution of antipsoriatic therapy.